DZ2521A1 - Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l'insuline pour une méthode de traitement. - Google Patents

Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l'insuline pour une méthode de traitement.

Info

Publication number
DZ2521A1
DZ2521A1 DZ980131A DZ980131A DZ2521A1 DZ 2521 A1 DZ2521 A1 DZ 2521A1 DZ 980131 A DZ980131 A DZ 980131A DZ 980131 A DZ980131 A DZ 980131A DZ 2521 A1 DZ2521 A1 DZ 2521A1
Authority
DZ
Algeria
Prior art keywords
ethoxyübenzylü
thiazolidine
dione
pyridyl
insulin
Prior art date
Application number
DZ980131A
Other languages
English (en)
French (fr)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2521A1 publication Critical patent/DZ2521A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
DZ980131A 1997-06-18 1998-06-17 Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l'insuline pour une méthode de traitement. DZ2521A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
DZ2521A1 true DZ2521A1 (fr) 2003-02-08

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980131A DZ2521A1 (fr) 1997-06-18 1998-06-17 Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l'insuline pour une méthode de traitement.

Country Status (30)

Country Link
EP (1) EP0999837A1 (id)
JP (1) JP2002504138A (id)
KR (1) KR20010013843A (id)
CN (1) CN1133431C (id)
AP (1) AP1287A (id)
AR (2) AR012997A1 (id)
AU (1) AU8216398A (id)
BG (1) BG104059A (id)
BR (1) BR9810444A (id)
CA (1) CA2294141A1 (id)
CO (1) CO4940454A1 (id)
DZ (1) DZ2521A1 (id)
EA (1) EA004800B1 (id)
GB (1) GB9712866D0 (id)
HU (1) HUP0003260A3 (id)
ID (1) ID23951A (id)
IL (1) IL133143A0 (id)
IN (1) IN189723B (id)
MA (1) MA26511A1 (id)
NO (1) NO996265L (id)
OA (1) OA11517A (id)
PE (1) PE104499A1 (id)
PL (1) PL343123A1 (id)
SK (1) SK179399A3 (id)
TR (1) TR199903095T2 (id)
TW (1) TW587937B (id)
UA (1) UA70299C2 (id)
UY (1) UY25050A1 (id)
WO (1) WO1998057636A1 (id)
ZA (1) ZA985237B (id)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
WO2000078333A2 (en) 1999-06-21 2000-12-28 Eli Lilly And Company Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
MXPA05004743A (es) 2002-11-08 2005-08-03 Hoffmann La Roche Derivados 4-alcoxioxazol sustituidos como agonistas ppar.
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719140B1 (en) * 1993-09-15 2007-10-31 Daiichi Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
KR19990045756A (ko) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 Ｒｘｒ 작용제를 이용하는 ｎｉｄｄｍ 치료 방법

Also Published As

Publication number Publication date
TW587937B (en) 2004-05-21
CO4940454A1 (es) 2000-07-24
PL343123A1 (en) 2001-07-30
CN1260715A (zh) 2000-07-19
AU8216398A (en) 1999-01-04
SK179399A3 (en) 2000-11-07
EA004800B1 (ru) 2004-08-26
BR9810444A (pt) 2000-09-05
CA2294141A1 (en) 1998-12-23
CN1133431C (zh) 2004-01-07
KR20010013843A (ko) 2001-02-26
AP1287A (en) 2004-06-26
AP9901718A0 (en) 1999-12-31
NO996265D0 (no) 1999-12-17
ID23951A (id) 2000-06-08
NO996265L (no) 1999-12-17
UY25050A1 (es) 2000-09-29
BG104059A (en) 2000-10-31
WO1998057636A1 (en) 1998-12-23
IN189723B (id) 2003-04-19
OA11517A (en) 2004-02-04
HUP0003260A3 (en) 2001-12-28
AR012997A1 (es) 2000-11-22
MA26511A1 (fr) 2004-12-20
HUP0003260A2 (hu) 2001-05-28
ZA985237B (en) 2000-02-17
EP0999837A1 (en) 2000-05-17
JP2002504138A (ja) 2002-02-05
GB9712866D0 (en) 1997-08-20
AR015894A1 (es) 2001-05-30
PE104499A1 (es) 2000-01-13
IL133143A0 (en) 2001-03-19
UA70299C2 (en) 2004-10-15
TR199903095T2 (xx) 2000-08-21
EA200000042A1 (ru) 2000-08-28

Similar Documents

Publication Publication Date Title
DZ2521A1 (fr) Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l'insuline pour une méthode de traitement.
RU2159761C2 (ru) Замещенные 4-биарилмасляные или 5-биарилпентановые кислоты или их производные, способы их получения, фармацевтическая композиция и способ лечения
DZ2420A1 (fr) Formulations nouvelles comprenant l'amoxycilline et du clavulanate et procédé pour leur préparation.
ATE257703T1 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DZ2753A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant.
DZ2581A1 (fr) Dérivés d'acides aryloxyarylsulfonylaminohydroxamiques procédé pour leur préparation et compositionspharmaceutiques les contenant.
NL300057I2 (nl) Farmacologisch actieve 1,5-diaryl-3-gesubstitueerde-pyrazolen en werkwijze voor het synthetiseren e rvan.
MA26420A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
DZ2221A1 (fr) Trihydrate de mésylate de 5-(2-(4-(1,2-benzisothiazole-3-yi)-1-pipérazinyl)-éthyl)-6-chloro-1,3-dihydro-2h-indole-2-one, procédé pour sa préparation et compositions pharmaceutiques le contenant.
FR2732223B1 (fr) Composition pharmaceutique pour administration transdermique
MA26508A1 (fr) Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
NL300258I1 (nl) Farmaceutische samenstelling voor toepassing in debehandeling van diabetes.
MA26516A1 (fr) Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant.
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
DZ2539A1 (fr) Compositions pharmaceutiques pour le traitement dela résistance à l'insuline.
DZ2414A1 (fr) 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2600A1 (fr) Associations pharmaceutiques d'amlodipine et d'unestatine et procédé pour leur préparation.
DZ2550A1 (fr) Dérivés d'azétidinylpropylpipéridine procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26608A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.
FR2716075B1 (fr) Procédé pour renforcer l'efficacité d'un produit chimique agricole, renforçateur et composition de renforçateur utilisés dans ce procédé et composition chimique agricole comprenant ce renforçateur.
DE59609508D1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
DZ2510A1 (fr) Composition comprenant de la 5-Ä4-Ä2-(n-méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜthiazolidine-2,4-dione et procédé pour sa préparation.
NO972449L (no) Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on-1,1-dioksidderivater og preparater og fremgangsmåte for anvendelse derav
DZ2522A1 (fr) Composition comprenant un sensibilisant à l'insuline et secrétagogue d'insuline pour une méthode de traitement.
DZ2658A1 (fr) Formulations nouvelles de paroxétine et procédé pour leur préparation.